Assessment of the safety and efficacy of micronized encapsulated ferric pyrophosphate in patients with iron deficiency anaemia: a phase-IV open-label clinical study.
Belal Almajali, Giriraja Kv, Gowthamarajan Kuppusamy et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase-IV, open-label, single-arm clinical study assessed micronized encapsulated ferric pyrophosphate (MEFP) in 60 adults aged 18–60 years with moderate iron deficiency anaemia. Participants received oral MEFP daily for 12 weeks. Haemoglobin, MCHC, serum ferritin, transferrin saturation, packed cell volume and red blood cell count increased significantly from baseline. Adverse events were described as minimal, and no adverse effect on liver or renal function was reported. The abstract provides no numerical effect sizes, so the magnitude of these changes cannot be assessed.
Key findings
- After 12 weeks, haemoglobin and several red-cell indices increased significantly from baseline.
- Serum ferritin and transferrin saturation increased significantly from baseline.
- Adverse events were minimal, and no adverse effect on liver or renal function was reported.
Why it matters
The findings suggest that MEFP may improve haemoglobin and iron-store measures in adults with moderate iron deficiency anaemia, while showing no reported liver or renal safety signal during the study. These outcomes are clinically relevant, but the single-arm design and absence of numerical effect estimates limit conclusions about the size of benefit and comparative effectiveness.
What to keep in mind
The study was open-label and single-arm, with no comparator; the abstract reports no numerical effect estimates.